The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1

Research output: Contribution to journalArticle

Standard

The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1. / Barini, Erica; Miccoli, Ageo; Tinarelli, Federico; Mulholland, Katie; Kadri, Hachemi; Khanim, Farhat; Stojanovski, Laste; Read, Kevin D.; Burness, Kerry; Blow, Julian J.; Mehellou, Youcef; Muqit, Miratul M. K.

In: ChemBioChem, Vol. 19, No. 5, 02.03.2018, p. 425-429.

Research output: Contribution to journalArticle

Harvard

Barini, E, Miccoli, A, Tinarelli, F, Mulholland, K, Kadri, H, Khanim, F, Stojanovski, L, Read, KD, Burness, K, Blow, JJ, Mehellou, Y & Muqit, MMK 2018, 'The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1', ChemBioChem, vol. 19, no. 5, pp. 425-429. https://doi.org/10.1002/cbic.201700500

APA

Barini, E., Miccoli, A., Tinarelli, F., Mulholland, K., Kadri, H., Khanim, F., Stojanovski, L., Read, K. D., Burness, K., Blow, J. J., Mehellou, Y., & Muqit, M. M. K. (2018). The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1. ChemBioChem, 19(5), 425-429. https://doi.org/10.1002/cbic.201700500

Vancouver

Author

Barini, Erica ; Miccoli, Ageo ; Tinarelli, Federico ; Mulholland, Katie ; Kadri, Hachemi ; Khanim, Farhat ; Stojanovski, Laste ; Read, Kevin D. ; Burness, Kerry ; Blow, Julian J. ; Mehellou, Youcef ; Muqit, Miratul M. K. / The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1. In: ChemBioChem. 2018 ; Vol. 19, No. 5. pp. 425-429.

Bibtex

@article{a4773be9b4c3455aa2df04e3970f6c6f,
title = "The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1",
abstract = "Mutations in PINK1, which impair its catalytic kinase activity, are causal for autosomal recessive early-onset Parkinson's disease (PD). Various studies have indicated that the activation of PINK1 could be a useful strategy in treating neurodegenerative diseases, such as PD. Herein, it is shown that the anthelmintic drug niclosamide and its analogues are capable of activating PINK1 in cells through the reversible impairment of the mitochondrial membrane potential. With these compounds, for the first time, it is demonstrated that the PINK1 pathway is active and detectable in primary neurons. These findings suggest that niclosamide and its analogues are robust compounds for the study of the PINK1 pathway and may hold promise as a therapeutic strategy in PD and related disorders.",
keywords = "Journal Article, drug discovery , membranes , mitochondria , neurodegenerative diseases , proteins",
author = "Erica Barini and Ageo Miccoli and Federico Tinarelli and Katie Mulholland and Hachemi Kadri and Farhat Khanim and Laste Stojanovski and Read, {Kevin D.} and Kerry Burness and Blow, {Julian J.} and Youcef Mehellou and Muqit, {Miratul M. K.}",
note = "{\textcopyright} 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.",
year = "2018",
month = mar
day = "2",
doi = "10.1002/cbic.201700500",
language = "English",
volume = "19",
pages = "425--429",
journal = "ChemBioChem",
issn = "1439-4227",
publisher = "Wiley-VCH Verlag",
number = "5",

}

RIS

TY - JOUR

T1 - The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1

AU - Barini, Erica

AU - Miccoli, Ageo

AU - Tinarelli, Federico

AU - Mulholland, Katie

AU - Kadri, Hachemi

AU - Khanim, Farhat

AU - Stojanovski, Laste

AU - Read, Kevin D.

AU - Burness, Kerry

AU - Blow, Julian J.

AU - Mehellou, Youcef

AU - Muqit, Miratul M. K.

N1 - © 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

PY - 2018/3/2

Y1 - 2018/3/2

N2 - Mutations in PINK1, which impair its catalytic kinase activity, are causal for autosomal recessive early-onset Parkinson's disease (PD). Various studies have indicated that the activation of PINK1 could be a useful strategy in treating neurodegenerative diseases, such as PD. Herein, it is shown that the anthelmintic drug niclosamide and its analogues are capable of activating PINK1 in cells through the reversible impairment of the mitochondrial membrane potential. With these compounds, for the first time, it is demonstrated that the PINK1 pathway is active and detectable in primary neurons. These findings suggest that niclosamide and its analogues are robust compounds for the study of the PINK1 pathway and may hold promise as a therapeutic strategy in PD and related disorders.

AB - Mutations in PINK1, which impair its catalytic kinase activity, are causal for autosomal recessive early-onset Parkinson's disease (PD). Various studies have indicated that the activation of PINK1 could be a useful strategy in treating neurodegenerative diseases, such as PD. Herein, it is shown that the anthelmintic drug niclosamide and its analogues are capable of activating PINK1 in cells through the reversible impairment of the mitochondrial membrane potential. With these compounds, for the first time, it is demonstrated that the PINK1 pathway is active and detectable in primary neurons. These findings suggest that niclosamide and its analogues are robust compounds for the study of the PINK1 pathway and may hold promise as a therapeutic strategy in PD and related disorders.

KW - Journal Article

KW - drug discovery

KW - membranes

KW - mitochondria

KW - neurodegenerative diseases

KW - proteins

U2 - 10.1002/cbic.201700500

DO - 10.1002/cbic.201700500

M3 - Article

C2 - 29226533

VL - 19

SP - 425

EP - 429

JO - ChemBioChem

JF - ChemBioChem

SN - 1439-4227

IS - 5

ER -